Teva- Pharmaceutical Industries Ltd. TEVA

NYS: TEVA | ISIN: US8816242098   1/05/2025
15,62 USD (+0,71%)
(+0,71%)   1/05/2025

7 april 2025 · Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States · Persbericht

7 april 2025 · Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention · Persbericht

31 maart 2025 · New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable · Persbericht

27 maart 2025 · Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025 · Persbericht

27 maart 2025 · Teva Releases Q1 2025 Aide Memoire · Persbericht

3 maart 2025 · Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March · Persbericht

27 februari 2025 · 2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals · Persbericht

25 februari 2025 · Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder · Persbericht

22 februari 2025 · Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease · Persbericht

21 februari 2025 · Les besoins du patient au centre de toutes les priorités : pourquoi l’Europe doit agir pour protéger l’accès aux médicaments ? · Persbericht

21 februari 2025 · Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. · Persbericht

18 februari 2025 · Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO) · Persbericht

18 februari 2025 · Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) · Persbericht

29 januari 2025 · Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth · Persbericht

27 januari 2025 · Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) · Persbericht

14 januari 2025 · Teva annonce un partenariat en vue de commercialiser le candidat biosimilaire de Formycon à Eylea® (aflibercept) dans la majeure partie de l’Europe et en Israël · Persbericht

13 januari 2025 · Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel · Persbericht

10 januari 2025 · Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States · Persbericht

23 december 2024 · Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference · Persbericht

20 december 2024 · Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025 · Persbericht

Mijn selecties